263 related articles for article (PubMed ID: 16998799)
1. Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity.
D'Agnano I; Valentini A; Gatti G; Chersi A; Felsani A
J Cell Physiol; 2007 Jan; 210(1):72-80. PubMed ID: 16998799
[TBL] [Abstract][Full Text] [Related]
2. Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization.
Lu X; Vogt PK; Boger DL; Lunec J
Oncol Rep; 2008 Mar; 19(3):825-30. PubMed ID: 18288422
[TBL] [Abstract][Full Text] [Related]
3. Elucidation of the structural determinants responsible for the specific formation of heterodimeric Mxd1/Max b-HLH-LZ and its binding to E-box sequences.
Montagne M; Naud JF; Lavigne P
J Mol Biol; 2008 Feb; 376(1):141-52. PubMed ID: 18155722
[TBL] [Abstract][Full Text] [Related]
4. myc, max, and a novel rlf-L-myc fusion protein in small-cell lung cancer.
Västrik I; Mäkelä TP; Koskinen PJ; Saksela K; Alitalo K
Princess Takamatsu Symp; 1991; 22():307-18. PubMed ID: 1668890
[TBL] [Abstract][Full Text] [Related]
5. Upstream stimulatory factor (USF) as a transcriptional suppressor of human telomerase reverse transcriptase (hTERT) in oral cancer cells.
Chang JT; Yang HT; Wang TC; Cheng AJ
Mol Carcinog; 2005 Nov; 44(3):183-92. PubMed ID: 16010690
[TBL] [Abstract][Full Text] [Related]
6. Synergistic induction of the Fas (CD95) ligand promoter by Max and NFkappaB in human non-small lung cancer cells.
Wiener Z; Ontsouka EC; Jakob S; Torgler R; Falus A; Mueller C; Brunner T
Exp Cell Res; 2004 Sep; 299(1):227-35. PubMed ID: 15302589
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of cancer cell growth and c-Myc transcriptional activity by a c-Myc helix 1-type peptide fused to an internalization sequence.
Giorello L; Clerico L; Pescarolo MP; Vikhanskaya F; Salmona M; Colella G; Bruno S; Mancuso T; Bagnasco L; Russo P; Parodi S
Cancer Res; 1998 Aug; 58(16):3654-9. PubMed ID: 9721875
[TBL] [Abstract][Full Text] [Related]
8. Insights into the mechanism of heterodimerization from the 1H-NMR solution structure of the c-Myc-Max heterodimeric leucine zipper.
Lavigne P; Crump MP; Gagné SM; Hodges RS; Kay CM; Sykes BD
J Mol Biol; 1998 Aug; 281(1):165-81. PubMed ID: 9680483
[TBL] [Abstract][Full Text] [Related]
9. Low molecular weight inhibitors of Myc-Max interaction and function.
Yin X; Giap C; Lazo JS; Prochownik EV
Oncogene; 2003 Sep; 22(40):6151-9. PubMed ID: 13679853
[TBL] [Abstract][Full Text] [Related]
10. Mouse Sin3A interacts with and can functionally substitute for the amino-terminal repression of the Myc antagonist Mxi1.
Rao G; Alland L; Guida P; Schreiber-Agus N; Chen K; Chin L; Rochelle JM; Seldin MF; Skoultchi AI; DePinho RA
Oncogene; 1996 Mar; 12(5):1165-72. PubMed ID: 8649810
[TBL] [Abstract][Full Text] [Related]
11. The Max homodimeric b-HLH-LZ significantly interferes with the specific heterodimerization between the c-Myc and Max b-HLH-LZ in absence of DNA: a quantitative analysis.
McDuff FO; Naud JF; Montagne M; Sauvé S; Lavigne P
J Mol Recognit; 2009; 22(4):261-9. PubMed ID: 19189276
[TBL] [Abstract][Full Text] [Related]
12. New structural determinants for c-Myc specific heterodimerization with Max and development of a novel homodimeric c-Myc b-HLH-LZ.
Beaulieu ME; McDuff FO; Frappier V; Montagne M; Naud JF; Lavigne P
J Mol Recognit; 2012 Jul; 25(7):414-26. PubMed ID: 22733550
[TBL] [Abstract][Full Text] [Related]
13. Decreased tumorigenicity of c-Myc-transformed fibroblasts expressing active USF2.
Choe C; Chen N; Sawadogo M
Exp Cell Res; 2005 Jan; 302(1):1-10. PubMed ID: 15541720
[TBL] [Abstract][Full Text] [Related]
14. c-Myc creates an activation loop by transcriptionally repressing its own functional inhibitor, hMad4, in young fibroblasts, a loop lost in replicatively senescent fibroblasts.
Marcotte R; Chen JM; Huard S; Wang E
J Cell Biochem; 2005 Dec; 96(5):1071-85. PubMed ID: 16167342
[TBL] [Abstract][Full Text] [Related]
15. Identification of casein kinase II phosphorylation sites in Max: effects on DNA-binding kinetics of Max homo- and Myc/Max heterodimers.
Bousset K; Henriksson M; Lüscher-Firzlaff JM; Litchfield DW; Lüscher B
Oncogene; 1993 Dec; 8(12):3211-20. PubMed ID: 8247525
[TBL] [Abstract][Full Text] [Related]
16. Both the helix-loop-helix and the leucine zipper motifs of c-Myc contribute to its dimerization specificity with Max.
Davis LJ; Halazonetis TD
Oncogene; 1993 Jan; 8(1):125-32. PubMed ID: 8423990
[TBL] [Abstract][Full Text] [Related]
17. Mnt transcriptional repressor is functionally regulated during cell cycle progression.
Popov N; Wahlström T; Hurlin PJ; Henriksson M
Oncogene; 2005 Dec; 24(56):8326-37. PubMed ID: 16103876
[TBL] [Abstract][Full Text] [Related]
18. Lack of correlation between N-myc and MAX expression in neuroblastoma tumors and in cell lines: implication for N-myc-MAX complex formation.
Raschella G; Romeo A; Negroni A; Pucci S; Dominici C; Castello MA; Bevilacqua P; Felsani A; Calabretta B
Cancer Res; 1994 Apr; 54(8):2251-5. PubMed ID: 8174135
[TBL] [Abstract][Full Text] [Related]
19. Direct visualization of the binding of c-Myc/Max heterodimeric b-HLH-LZ to E-box sequences on the hTERT promoter.
Lebel R; McDuff FO; Lavigne P; Grandbois M
Biochemistry; 2007 Sep; 46(36):10279-86. PubMed ID: 17705400
[TBL] [Abstract][Full Text] [Related]
20. Loss of the Max-interacting protein Mnt in mice results in decreased viability, defective embryonic growth and craniofacial defects: relevance to Miller-Dieker syndrome.
Toyo-oka K; Hirotsune S; Gambello MJ; Zhou ZQ; Olson L; Rosenfeld MG; Eisenman R; Hurlin P; Wynshaw-Boris A
Hum Mol Genet; 2004 May; 13(10):1057-67. PubMed ID: 15028671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
